{"id":745016,"date":"2014-03-21T08:05:00","date_gmt":"2014-03-21T08:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/"},"modified":"2023-03-22T00:04:57","modified_gmt":"2023-03-22T04:04:57","slug":"merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/","title":{"rendered":"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant &#8230;"},"content":{"rendered":"<p class=\"bwalignc\">\n      <b>Merck and Endocyte Announce European CHMP Positive Opinions for<br \/>\n      VYNFINIT<\/b><sup><b>\u00ae<\/b><\/sup><b> (vintafolide) and Companion Imaging<br \/>\n      Agents FOLCEPRI<\/b><sup><b>\u00ae<\/b><\/sup><b> (etarfolatide) and NEOCEPRI<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      (Intravenous (IV) folic acid)<\/b> <b>in Patients with Platinum-Resistant<br \/>\n      Ovarian Cancer<\/b>\n    <\/p>\n<p>\n     WHITEHOUSE STATION, N.J. &amp; WEST LAFAYETTE, Ind.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211; Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Endocyte, Inc. (NASDAQ:ECYT), today announced that the Committee for<br \/>\n      Medicinal Products for Human Use (CHMP) of the European Medicines Agency<br \/>\n      (EMA) has issued positive opinions for the Conditional Marketing<br \/>\n      Authorisations of VYNFINIT<sup>\u00ae<\/sup> (vintafolide) and companion<br \/>\n      imaging components, imaging agent FOLCEPRI<sup>\u00ae<\/sup> (etarfolatide),<br \/>\n      and NEOCEPRI<sup>\u00ae<\/sup> (intravenous (IV) folic acid), for the<br \/>\n      treatment of adult patients with folate receptor-positive,<br \/>\n      platinum-resistant, ovarian cancer, in combination with pegylated<br \/>\n      liposomal doxorubicin (PLD).\n    <\/p>\n<p>\n      \u201cThese positive CHMP opinions bring Merck and Endocyte one step closer<br \/>\n      to providing a personalized approach to address a significant unmet<br \/>\n      medical need in platinum-resistant ovarian cancer,\u201d said Dr. Eric Rubin,<br \/>\n      vice president, Clinical Development for Oncology, Merck Research<br \/>\n      Laboratories. \u201cWe want to acknowledge our colleagues at Endocyte for<br \/>\n      their pioneering work in this field, and look forward to the European<br \/>\n      Commission completing their review of the applications.\u201d\n    <\/p>\n<p>\n      \u201cVintafolide is a folate receptor targeted agent, and if approved, would<br \/>\n      be the first oncology therapeutic to employ an imaging agent as a<br \/>\n      companion diagnostic for patient selection,\u201d said Ron Ellis, Endocyte\u2019s<br \/>\n      president and CEO. \u201cToday\u2019s positive CHMP opinions are an important step<br \/>\n      toward personalizing ovarian cancer management for appropriate patients,<br \/>\n      and validate our Company\u2019s focus on the development of targeted<br \/>\n      medicines and companion imaging agents designed to improve patient<br \/>\n      outcomes.\u201d\n    <\/p>\n<p>\n      Vintafolide is proposed for use in combination with PLD for the<br \/>\n      treatment of adult patients with platinum-resistant ovarian cancer who<br \/>\n      express the folate receptor on all target lesions. Folate receptor<br \/>\n      status should be assessed by a diagnostic medicinal product approved for<br \/>\n      the selection of adult patients for treatment with vintafolide, using<br \/>\n      Single Photon Emission Computed Tomography (SPECT) imaging, in<br \/>\n      combination with Computed Tomography (CT) or Magnetic Resonance Imaging<br \/>\n      (MRI).\n    <\/p>\n<p>\n      Etarfolatide and IV folic acid are medicinal products proposed for<br \/>\n      diagnostic use only. Etarfolatide, following radiolabelling with sodium<br \/>\n      pertechnetate (<sup>99m<\/sup>Tc) solution, is proposed for SPECT imaging<br \/>\n      in combination with CT or MRI, for the selection of adult patients for<br \/>\n      treatment with vintafolide. Intravenous folic acid would be<br \/>\n      administrated prior to <sup>99m<\/sup>Tc-etarfolatide for the enhancement<br \/>\n      of SPECT image quality.\n    <\/p>\n<p>\n      The applications for Conditional Marketing Authorisation for<br \/>\n      vintafolide, etarfolatide and IV folic acid were submitted based on<br \/>\n      results in platinum-resistant ovarian cancer patients who express the<br \/>\n      folate receptor on all target lesions as evaluated in the PRECEDENT<br \/>\n      Phase 2 study (ClinicalTrials.gov Identifier: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00722592%3Fterm%3DNCT00722592%26rank%3D1&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=NCT00722592&amp;index=1&amp;md5=3eb1fc37dd7abb02f3dbdafc09fa5e58\" rel=\"nofollow\">NCT00722592<\/a>).\n    <\/p>\n<p>\n      The CHMP positive opinions will be reviewed by the European Commission<br \/>\n      (EC). If approved, the EC grants a centralized marketing authorization<br \/>\n      with unified labeling that is valid in the 28 countries that are members<br \/>\n      of the European Union, as well as European Economic Area members<br \/>\n      Iceland, Liechtenstein and Norway. The EC usually issues a final legally<br \/>\n      binding decision within three months of a CHMP opinion.\n    <\/p>\n<p>\n      <b>About vintafolide, etarfolatide and IV folic acid<\/b>\n    <\/p>\n<p>\n      Vintafolide is an investigational conjugate of folic acid (vitamin B9)<br \/>\n      linked to an anti-cancer agent, the potent vinca alkaloid<br \/>\n      desacetylvinblastine hydrazide (DAVLBH). Since cancer cells generally<br \/>\n      consume higher levels of folate than normal cells to fuel their growth,<br \/>\n      some cancer cell types \u2013 including ovarian \u2013 have high concentrations of<br \/>\n      the folate receptor on their surface. Vintafolide is designed to<br \/>\n      selectively target the folate receptor to deliver the anti-cancer agent<br \/>\n      to the cancerous tissue. Tumors that have high concentrations of the<br \/>\n      folate receptor are identified by etarfolatide, a non-invasive imaging<br \/>\n      diagnostic agent. Intravenous folic acid is used with <sup>99m<\/sup>Tc-etarfolatide<br \/>\n      for the enhancement of image quality.\n    <\/p>\n<p>\n      Vintafolide, etarfolatide and IV folic acid have been granted orphan<br \/>\n      drug status by the EMA.<b> <\/b>The U.S. Food and Drug Administration has<br \/>\n      also granted orphan drug status to vintafolide and etarfolatide. Further<br \/>\n      evaluation is ongoing in the global PROCEED Phase 3 clinical trial in<br \/>\n      folate receptor-positive (FR 100%), platinum-resistant ovarian cancer (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fnct01170650%3Fterm%3Dvintafolide%26rank%3D7&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=ClinicalTrials.gov+Identifier%3A+NCT01170650&amp;index=2&amp;md5=48c7a41cf9aa8e61138e8933a2cac141\" rel=\"nofollow\">ClinicalTrials.gov<br \/>\n      Identifier: NCT01170650<\/a>). The randomized TARGET Phase 2b study of<br \/>\n      vintafolide in non-small cell lung cancer has completed enrollment<br \/>\n      (ClinicalTrials.gov Identifier: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01577654%3Fterm%3DNCT01577654%26rank%3D1&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=NCT01577654&amp;index=3&amp;md5=886dd7a189098bb84da8a7631d1d1484\" rel=\"nofollow\">NCT01577654<\/a>),<br \/>\n      and a Phase 2 study in triple-negative breast cancer is expected to be<br \/>\n      initiated in Q2 (ClinicalTrials.gov Identifier: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01953536&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=NCT01953536&amp;index=4&amp;md5=ce29c70187638557497d712224556734\" rel=\"nofollow\">NCT01953536<\/a>).\n    <\/p>\n<p>\n      <b>About Folate Receptor-Positive Platinum-Resistant Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      In 2012, it was estimated that there would be over 40,000 new cases of<br \/>\n      ovarian cancer in the European Union. Ovarian cancer is one of the most<br \/>\n      lethal cancers of the female reproductive system. Overall, approximately<br \/>\n      80 percent of patients relapse after first-line, platinum-based,<br \/>\n      chemotherapy. Platinum-resistant ovarian cancer, also known as PROC, is<br \/>\n      a challenging disease with a high unmet need for new treatments. This<br \/>\n      type of cancer recurs within six months of completion of a<br \/>\n      platinum-containing regimen, the standard of care for ovarian cancer. An<br \/>\n      estimated 80 percent of platinum-resistant ovarian cancer patients have<br \/>\n      been found to have folate receptor-positive disease, and approximately<br \/>\n      40 percent express the receptor, as detected by etarfolatide, in all of<br \/>\n      their target tumor lesions (FR 100%). Compared to patients who do not<br \/>\n      express folate receptors on their tumors, folate receptor-positive<br \/>\n      patients have been shown to have a poorer overall prognosis.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=44f0afd998569f57a928afbc6a3aa557\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=ec31fd22b77bf7456865773c0daf3cbb\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=8ca621e5e759942b3b2378e82e1d64a7\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>About Endocyte<\/b>\n    <\/p>\n<p>\n      Endocyte is a biopharmaceutical company and leader in developing<br \/>\n      targeted small molecule drug conjugates (SMDCs) and companion imaging<br \/>\n      agents for personalized therapy in cancer and other serious diseases.<br \/>\n      Endocyte uses its proprietary technology to create novel SMDCs and<br \/>\n      companion imaging agents for personalized targeted therapies. The<br \/>\n      company&#8217;s SMDCs actively target receptors that are expressed or<br \/>\n      over-expressed on diseased cells, relative to healthy cells. This<br \/>\n      targeted approach is designed to enable the treatment of patients with<br \/>\n      highly potent drugs into these cells. The companion imaging agents are<br \/>\n      designed to identify patients whose disease expresses the molecular<br \/>\n      target of the therapy and who therefore may be more likely to benefit<br \/>\n      from treatment. For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.endocyte.com&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.endocyte.com&amp;index=8&amp;md5=e4dde0463e43de9da0c092f112892588\" rel=\"nofollow\">http:\/\/www.endocyte.com<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50829395&amp;newsitemid=20140321005237&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=7ce0a75d6af46bf1c9d8bd2cdeb1728a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Endocyte Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      Certain of the statements made in this press release are forward<br \/>\n      looking, such as those, among others, relating to the company&#8217;s<br \/>\n      expectations for seeking regulatory approval and commercial launch of<br \/>\n      its products, including any conditional marketing authorization from the<br \/>\n      EMA, initiation of future clinical trials, and expectations for the<br \/>\n      receipt of milestones, royalties or other profits from the company\u2019s<br \/>\n      partnership with Merck. Actual results or developments may differ<br \/>\n      materially from those projected or implied in these forward-looking<br \/>\n      statements. Factors that may cause such a difference include risks that<br \/>\n      the company may experience delays in the completion of its clinical<br \/>\n      trials (whether caused by competition, adverse events, patient<br \/>\n      enrollment rates, unavailability of clinical trial materials, regulatory<br \/>\n      issues or other factors); risks that data from its clinical trials may<br \/>\n      not be indicative of subsequent clinical trial results; risks related to<br \/>\n      the safety and efficacy of the company&#8217;s product candidates, the goals<br \/>\n      of its development activities, estimates of the potential markets for<br \/>\n      its product candidates, estimates of the capacity of manufacturing and<br \/>\n      other facilities required to support its product candidates, projected<br \/>\n      cash needs, and expected financial results. More information about the<br \/>\n      risks and uncertainties faced by Endocyte, Inc. is contained in the<br \/>\n      company&#8217;s periodic reports filed with the Securities and Exchange<br \/>\n      Commission. Endocyte, Inc. disclaims any intention or obligation to<br \/>\n      update or revise any forward-looking statements, whether as a result of<br \/>\n      new information, future events or otherwise.\n    <\/p>\n<p>\n      VYNFINIT<sup>\u00ae<\/sup> is a registered trademark of Merck &amp; Co., Inc.,<br \/>\n      Whitehouse Station, N.J., USA.\n    <\/p>\n<p>\n      FOLCEPRI<sup>\u00ae<\/sup> and NEOCEPRI<sup>\u00ae<\/sup> are registered trademarks<br \/>\n      of&nbsp;Endocyte, Inc.\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140321005237r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20140321005237\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20140321005237\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, +1 908-423-3046<br \/>Claire        Mulhearn, +1 908-423-7425<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        +1 908-423-4465<br \/>Justin Holko, +1 908-423-5088<br \/>or<br \/>Endocyte<br \/>Media:<br \/>Martina        Schwarzkopf, +1 212-845-4292<br \/>Tony Russo, +1 212-845-4251<br \/>or<br \/>Investors:<br \/>Stephanie        Ascher, +1 212-362-1200     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT \u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI \u00ae (etarfolatide) and NEOCEPRI \u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer WHITEHOUSE STATION, N.J. &amp; WEST LAFAYETTE, Ind.-(BUSINESS WIRE)- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for the Conditional Marketing Authorisations of VYNFINIT\u00ae (vintafolide) and companion imaging components, imaging agent FOLCEPRI\u00ae (etarfolatide), and NEOCEPRI\u00ae (intravenous (IV) folic acid), for the treatment of adult patients with folate receptor-positive, platinum-resistant, ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD). \u201cThese positive CHMP opinions bring Merck and Endocyte one step closer to providing a<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-745016","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ... - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ... - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT \u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI \u00ae (etarfolatide) and NEOCEPRI \u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer WHITEHOUSE STATION, N.J. &amp; WEST LAFAYETTE, Ind.-(BUSINESS WIRE)- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for the Conditional Marketing Authorisations of VYNFINIT\u00ae (vintafolide) and companion imaging components, imaging agent FOLCEPRI\u00ae (etarfolatide), and NEOCEPRI\u00ae (intravenous (IV) folic acid), for the treatment of adult patients with folate receptor-positive, platinum-resistant, ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD). \u201cThese positive CHMP opinions bring Merck and Endocyte one step closer to providing a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\\\/\",\"name\":\"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ... - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-03-21T08:05:00+00:00\",\"dateModified\":\"2023-03-22T04:04:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant &#8230;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ... - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ... - Merck.com","og_description":"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT \u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI \u00ae (etarfolatide) and NEOCEPRI \u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer WHITEHOUSE STATION, N.J. &amp; WEST LAFAYETTE, Ind.-(BUSINESS WIRE)- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for the Conditional Marketing Authorisations of VYNFINIT\u00ae (vintafolide) and companion imaging components, imaging agent FOLCEPRI\u00ae (etarfolatide), and NEOCEPRI\u00ae (intravenous (IV) folic acid), for the treatment of adult patients with folate receptor-positive, platinum-resistant, ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD). \u201cThese positive CHMP opinions bring Merck and Endocyte one step closer to providing a","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:57+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/","name":"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ... - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-03-21T08:05:00+00:00","dateModified":"2023-03-22T04:04:57+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-vintafolide-and-companion-imaging-agents-folcepri-etarfolatide-and-neocepri-intravenous-iv-folic-acid\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT\u00ae (vintafolide) and Companion Imaging Agents FOLCEPRI\u00ae (etarfolatide) and NEOCEPRI\u00ae (Intravenous (IV) folic acid) in Patients with Platinum-Resistant &#8230;"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"81112cb6-0d58-4376-84df-e96dc4ed8205","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/03\/1\/edologo.jpg","size":"27591","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/03\/1\/logo_merck-logo.jpg","size":"13027","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Endocyte-Announce-European-CHMP-Positive-Opinions-for-VYNFINIT-vintafolide-and-Companion-Imaging-Agents-FOLCEPRI-etarfolati-YTZJK.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745016\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745016"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}